NCT07317544: Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic Alopecia
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 227 planned
- Started
- 3 Dec 2025
- Primary completion
- Jul 2028
- Arms
- SAD IV Dose 1 - 150mg ABS201 or Placebo, SAD IV Dose 2 - 450mg ABS201 or Placebo, SAD IV Dose 3 - 900mg ABS201 or Placebo, SAD IV Dose 4 - 1800mg ABS201 or Placebo
- Results
- None posted
- 3 Dec 2025: Trial started
- 5 Jan 2026: Trial registered